Format

Send to

Choose Destination
Trends Cancer. 2018 Jul;4(7):499-512. doi: 10.1016/j.trecan.2018.05.006. Epub 2018 Jun 13.

Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection.

Author information

1
Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.
2
Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA; Department of Chemistry, University of California, Berkeley, CA 94720, USA; Howard Hughes Medical Institute, University of California, Berkeley, CA 94720, USA; MBIB Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA; Innovative Genomics Institute, University of California, Berkeley, CA 94720, USA. Electronic address: doudna@berkeley.edu.

Abstract

Cancer is a complex disease caused by combinations of cellular genetic alterations and heterogeneous microenvironments. The use of the robust and programmable CRISPR-Cas systems has greatly improved genome editing for precision cancer modeling and enabled multiplexed genetic manipulation for cancer treatment and mutation detection. In this review, we outline the current CRISPR-Cas toolkit, and discuss the promises and hurdles in translating this revolutionary technology into effective and safe clinical applications for cancer treatment and diagnosis.

PMID:
29937048
PMCID:
PMC6299457
[Available on 2019-07-01]
DOI:
10.1016/j.trecan.2018.05.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center